0 XP   0   0   0

OKYO Pharma Ltd ADR
Buy, Hold or Sell?

Let's analyse OKYO Pharma Ltd ADR together

PenkeI guess you are interested in OKYO Pharma Ltd ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of OKYO Pharma Ltd ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about OKYO Pharma Ltd ADR

I send you an email if I find something interesting about OKYO Pharma Ltd ADR.

Quick analysis of OKYO Pharma Ltd ADR (30 sec.)










1. Valuation of OKYO Pharma Ltd ADR (5 min.)




Current price per share

$1.63

2. Growth of OKYO Pharma Ltd ADR (5 min.)




Is OKYO Pharma Ltd ADR growing?

Current yearPrevious yearGrowGrow %
How rich?$560.9k$1.9m-$1.6m-471.9%

How much money is OKYO Pharma Ltd ADR making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$820.4k-$213.1k?
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of OKYO Pharma Ltd ADR (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#977 / 1215

Most Revenue
#809 / 1215

Most Profit
#499 / 1215

Most Efficient
#225 / 1215


Fundamentals of OKYO Pharma Ltd ADR

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of OKYO Pharma Ltd ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit OKYO Pharma Ltd ADR earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of OKYO Pharma Ltd ADR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--194.7%+194.7%
TTM--276.2%+276.2%
YOY--313.0%+313.0%
5Y--539.0%+539.0%
10Y--664.9%+664.9%
1.1.2. Return on Assets

Shows how efficient OKYO Pharma Ltd ADR is using its assets to generate profit.

  • Above 5% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • -126.3% Return on Assets means that OKYO Pharma Ltd ADR generated $-1.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of OKYO Pharma Ltd ADR:

  • The MRQ is -126.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -111.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-126.3%TTM-111.0%-15.3%
TTM-111.0%YOY-41.5%-69.4%
TTM-111.0%5Y-771.9%+660.9%
5Y-771.9%10Y-425.4%-346.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-126.3%-12.4%-113.9%
TTM-111.0%-12.5%-98.5%
YOY-41.5%-10.9%-30.6%
5Y-771.9%-15.3%-756.6%
10Y-425.4%-17.6%-407.8%
1.1.3. Return on Equity

Shows how efficient OKYO Pharma Ltd ADR is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • -184.3% Return on Equity means OKYO Pharma Ltd ADR generated $-1.84 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of OKYO Pharma Ltd ADR:

  • The MRQ is -184.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -138.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-184.3%TTM-138.2%-46.1%
TTM-138.2%YOY-55.5%-82.7%
TTM-138.2%5Y-877.0%+738.8%
5Y-877.0%10Y-479.6%-397.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-184.3%-15.2%-169.1%
TTM-138.2%-15.5%-122.7%
YOY-55.5%-13.1%-42.4%
5Y-877.0%-20.4%-856.6%
10Y-479.6%-20.9%-458.7%

1.2. Operating Efficiency of OKYO Pharma Ltd ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient OKYO Pharma Ltd ADR is operating .

  • Measures how much profit OKYO Pharma Ltd ADR makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of OKYO Pharma Ltd ADR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--319.9%+319.9%
TTM--274.8%+274.8%
YOY--333.1%+333.1%
5Y--517.0%+517.0%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient OKYO Pharma Ltd ADR is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of OKYO Pharma Ltd ADR:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.013-3.013
TTM-3.665-3.665
YOY-4.530-4.530
5Y-6.411-6.411
10Y-8.337-8.337

1.3. Liquidity of OKYO Pharma Ltd ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if OKYO Pharma Ltd ADR is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.17 means the company has $3.17 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of OKYO Pharma Ltd ADR:

  • The MRQ is 3.174. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.589. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.174TTM2.589+0.585
TTM2.589YOY5.076-2.487
TTM2.5895Y5.640-3.051
5Y5.64010Y22.019-16.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1744.560-1.386
TTM2.5894.996-2.407
YOY5.0766.164-1.088
5Y5.6406.306-0.666
10Y22.0196.588+15.431
1.3.2. Quick Ratio

Measures if OKYO Pharma Ltd ADR is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • A Quick Ratio of 19.76 means the company can pay off $19.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of OKYO Pharma Ltd ADR:

  • The MRQ is 19.761. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.412. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ19.761TTM6.412+13.349
TTM6.412YOY4.923+1.488
TTM6.4125Y6.361+0.051
5Y6.36110Y22.158-15.797
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.7613.878+15.883
TTM6.4124.501+1.911
YOY4.9235.806-0.883
5Y6.3615.816+0.545
10Y22.1586.032+16.126

1.4. Solvency of OKYO Pharma Ltd ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of OKYO Pharma Ltd ADR assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare OKYO Pharma Ltd ADR to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.31 means that OKYO Pharma Ltd ADR assets are financed with 31.5% credit (debt) and the remaining percentage (100% - 31.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of OKYO Pharma Ltd ADR:

  • The MRQ is 0.315. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.535. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.315TTM0.535-0.220
TTM0.535YOY0.233+0.301
TTM0.5355Y0.515+0.019
5Y0.51510Y0.264+0.252
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3150.311+0.004
TTM0.5350.298+0.237
YOY0.2330.268-0.035
5Y0.5150.377+0.138
10Y0.2640.409-0.145
1.4.2. Debt to Equity Ratio

Measures if OKYO Pharma Ltd ADR is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • A Debt to Equity ratio of 45.9% means that company has $0.46 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of OKYO Pharma Ltd ADR:

  • The MRQ is 0.459. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.344. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.459TTM0.344+0.115
TTM0.344YOY0.315+0.029
TTM0.3445Y0.356-0.012
5Y0.35610Y0.184+0.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4590.363+0.096
TTM0.3440.362-0.018
YOY0.3150.277+0.038
5Y0.3560.425-0.069
10Y0.1840.463-0.279

2. Market Valuation of OKYO Pharma Ltd ADR

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings OKYO Pharma Ltd ADR generates.

  • Above 15 is considered overpriced but always compare OKYO Pharma Ltd ADR to the Biotechnology industry mean.
  • A PE ratio of -35.38 means the investor is paying $-35.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of OKYO Pharma Ltd ADR:

  • The EOD is -34.310. Company is losing money. -2
  • The MRQ is -35.384. Company is losing money. -2
  • The TTM is -43.808. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-34.310MRQ-35.384+1.074
MRQ-35.384TTM-43.808+8.425
TTM-43.808YOY--43.808
TTM-43.8085Y-8.762-35.047
5Y-8.76210Y-4.381-4.381
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-34.310-6.456-27.854
MRQ-35.384-7.202-28.182
TTM-43.808-8.445-35.363
YOY--19.899+19.899
5Y-8.762-18.384+9.622
10Y-4.381-18.346+13.965
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of OKYO Pharma Ltd ADR.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of OKYO Pharma Ltd ADR:

  • The MRQ is -35.384. Very Bad. -2
  • The TTM is -43.440. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-35.384TTM-43.440+8.057
TTM-43.4405Y-43.4400.000
5Y-43.44010Y-43.4400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.384-4.294-31.090
TTM-43.440-6.108-37.332
5Y-43.440-12.624-30.816
10Y-43.440-11.949-31.491

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of OKYO Pharma Ltd ADR is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 65.20 means the investor is paying $65.20 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of OKYO Pharma Ltd ADR:

  • The EOD is 63.221. Seems overpriced? -1
  • The MRQ is 65.200. Seems overpriced? -1
  • The TTM is 8.985. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD63.221MRQ65.200-1.979
MRQ65.200TTM8.985+56.215
TTM8.985YOY-+8.985
TTM8.9855Y1.797+7.188
5Y1.79710Y0.899+0.899
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD63.2211.888+61.333
MRQ65.2002.024+63.176
TTM8.9852.335+6.650
YOY-3.965-3.965
5Y1.7973.734-1.937
10Y0.8993.979-3.080
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of OKYO Pharma Ltd ADR.

3.1. Institutions holding OKYO Pharma Ltd ADR

Institutions are holding 0.029% of the shares of OKYO Pharma Ltd ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-12-31UBS Group AG0.0346075236341536.4636
2022-09-30Citadel Advisors Llc000-26864-100
Total 0.034607523-20523-272.8%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of OKYO Pharma Ltd ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.0190%-0.0180%-0.0030%-0.0330%
Book Value Growth--1.0001.127-11%1.665-40%17.490-94%9.623-90%
Book Value Per Share--0.0260.016+63%0.090-71%0.048-46%0.320-92%
Book Value Per Share Growth--1.0001.127-11%1.665-40%17.490-94%9.623-90%
Current Ratio--3.1742.589+23%5.076-37%5.640-44%22.019-86%
Debt To Asset Ratio--0.3150.535-41%0.233+35%0.515-39%0.264+19%
Debt To Equity Ratio--0.4590.344+33%0.315+46%0.356+29%0.184+149%
Dividend Per Share--0.2910.073+300%-+100%0.015+1900%0.007+3900%
Eps---0.047-0.0470%-0.046-4%-0.216+355%-0.169+256%
Eps Growth--1.0001.009-1%--1.009-1%1.009-1%
Free Cash Flow Per Share---0.048-0.0480%-0.023-52%-0.022-53%-0.032-32%
Free Cash Flow Per Share Growth--1.0001.0000%0.417+140%0.863+16%0.954+5%
Free Cash Flow To Equity Per Share---0.048-0.0480%0.003-1471%-0.015-68%-0.017-65%
Free Cash Flow To Equity Per Share Growth--1.0000.516+94%2.282-56%1.038-4%1.013-1%
Gross Profit Margin--1.0091.002+1%1.000+1%1.000+1%1.000+1%
Intrinsic Value_10Y_max--1.581--------
Intrinsic Value_10Y_min---1.907--------
Intrinsic Value_1Y_max---0.072--------
Intrinsic Value_1Y_min---0.192--------
Intrinsic Value_3Y_max---0.041--------
Intrinsic Value_3Y_min---0.581--------
Intrinsic Value_5Y_max--0.202--------
Intrinsic Value_5Y_min---0.968--------
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio63.221-3%65.2008.985+626%-+100%1.797+3528%0.899+7156%
Pe Ratio-34.310+3%-35.384-43.808+24%--100%-8.762-75%-4.381-88%
Peg Ratio---35.384-43.440+23%---43.440+23%-43.440+23%
Price Per Share1.629-3%1.6802.080-19%-+100%0.416+304%0.208+708%
Price To Total Gains Ratio5.595-3%5.771-9.850+271%---9.850+271%-9.850+271%
Profit Growth--1.0001.0000%0.905+10%0.990+1%-4.995+600%
Quick Ratio--19.7616.412+208%4.923+301%6.361+211%22.158-11%
Return On Assets---1.263-1.110-12%-0.415-67%-7.719+511%-4.254+237%
Return On Equity---1.843-1.382-25%-0.555-70%-8.770+376%-4.796+160%
Total Gains Per Share--0.2910.053+445%-0.018+106%0.011+2444%-0.026+109%
Total Gains Per Share Growth--7.2802.612+179%0.917+694%4.617+58%2.764+163%
Usd Book Value--560942.180343286.885+63%1963250.180-71%1034146.088-46%6971385.582-92%
Usd Book Value Change Per Share----0.0190%-0.0180%-0.0030%-0.0330%
Usd Book Value Per Share--0.0260.016+63%0.090-71%0.048-46%0.320-92%
Usd Dividend Per Share--0.2910.073+300%-+100%0.015+1900%0.007+3900%
Usd Eps---0.047-0.0470%-0.046-4%-0.216+355%-0.169+256%
Usd Free Cash Flow---1040986.100-1040986.1000%-494624.150-52%-489696.213-53%-706320.863-32%
Usd Free Cash Flow Per Share---0.048-0.0480%-0.023-52%-0.022-53%-0.032-32%
Usd Free Cash Flow To Equity Per Share---0.048-0.0480%0.003-1471%-0.015-68%-0.017-65%
Usd Price Per Share1.629-3%1.6802.080-19%-+100%0.416+304%0.208+708%
Usd Profit---1033622.910-1033622.9100%-820423.665-21%-4612309.315+346%-3637964.976+252%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.2910.053+445%-0.018+106%0.011+2444%-0.026+109%
 EOD+2 -3MRQTTM+15 -10YOY+11 -215Y+18 -1710Y+16 -19

4.2. Fundamental Score

Let's check the fundamental score of OKYO Pharma Ltd ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-34.310
Price to Book Ratio (EOD)Between0-163.221
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than119.761
Current Ratio (MRQ)Greater than13.174
Debt to Asset Ratio (MRQ)Less than10.315
Debt to Equity Ratio (MRQ)Less than10.459
Return on Equity (MRQ)Greater than0.15-1.843
Return on Assets (MRQ)Greater than0.05-1.263
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of OKYO Pharma Ltd ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.523
Ma 20Greater thanMa 501.608
Ma 50Greater thanMa 1001.472
Ma 100Greater thanMa 2001.852
OpenGreater thanClose1.550
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets818
Total Liabilities258
Total Stockholder Equity561
 As reported
Total Liabilities 258
Total Stockholder Equity+ 561
Total Assets = 818

Assets

Total Assets818
Total Current Assets817
Long-term Assets817
Total Current Assets
Cash And Cash Equivalents 514
Short-term Investments 4,407
Net Receivables 168
Total Current Assets  (as reported)817
Total Current Assets  (calculated)5,089
+/- 4,272
Long-term Assets
Property Plant Equipment 1
Goodwill 215
Intangible Assets 125
Long-term Assets  (as reported)1
Long-term Assets  (calculated)341
+/- 340

Liabilities & Shareholders' Equity

Total Current Liabilities258
Long-term Liabilities5
Total Stockholder Equity561
Total Current Liabilities
Accounts payable 141
Other Current Liabilities 116
Total Current Liabilities  (as reported)258
Total Current Liabilities  (calculated)258
+/- 0
Long-term Liabilities
Long-term Liabilities  (as reported)5
Long-term Liabilities  (calculated)0
+/- 5
Total Stockholder Equity
Common Stock23,595
Retained Earnings -21,397
Accumulated Other Comprehensive Income -1
Total Stockholder Equity (as reported)561
Total Stockholder Equity (calculated)2,197
+/- 1,636
Other
Cash and Short Term Investments 514
Common Stock Shares Outstanding 15,065
Liabilities and Stockholders Equity 818
Net Debt -514
Short Long Term Debt Total 6



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-31
> Total Assets 
3,478
3,478
3,478
3,478
6,678
6,678
6,678
6,678
35,920
8,980
10,001
8,980
10,013
2,503
2,503
2,503
26,357
6,589
30,594
6,589
29,748
7,437
23,428
7,437
28,363
7,091
27,759
7,091
22,992
5,748
22,669
5,748
22,395
5,599
22,388
5,599
22,246
5,562
2,876
5,562
2,008
502
1,260
502
583
146
502
146
483
121
5,840
121
5,138
1,285
4,177
1,285
3,274
818
1,589
818
818
8188181,5898183,2741,2854,1771,2855,1381215,8401214831465021465835021,2605022,0085,5622,8765,56222,2465,59922,3885,59922,3955,74822,6695,74822,9927,09127,7597,09128,3637,43723,4287,43729,7486,58930,5946,58926,3572,5032,5032,50310,0138,98010,0018,98035,9206,6786,6786,6786,6783,4783,4783,4783,478
   > Total Current Assets 
2,273
2,273
2,273
2,273
5,348
5,348
5,348
5,348
35,920
8,980
10,001
8,980
10,013
2,503
2,503
2,503
10,912
2,728
13,190
2,728
9,593
2,398
3,691
2,398
7,321
1,830
5,585
1,830
4,586
1,147
4,155
1,147
3,737
934
3,628
934
3,288
822
2,834
822
2,008
502
1,260
502
582
145
501
145
458
115
5,817
115
5,062
1,266
4,113
1,266
3,270
817
1,584
817
817
8178171,5848173,2701,2664,1131,2665,0621155,8171154581455011455825021,2605022,0088222,8348223,2889343,6289343,7371,1474,1551,1474,5861,8305,5851,8307,3212,3983,6912,3989,5932,72813,1902,72810,9122,5032,5032,50310,0138,98010,0018,98035,9205,3485,3485,3485,3482,2732,2732,2732,273
       Cash And Cash Equivalents 
2,264
2,264
2,264
2,264
940
940
940
940
17,677
4,419
9,990
4,419
10,001
2,500
2,500
2,500
10,640
2,660
12,938
2,660
9,437
2,359
3,511
2,359
7,104
1,776
5,348
1,776
4,366
1,091
3,942
1,091
3,569
892
3,443
892
3,146
786
2,667
786
2,008
502
1,244
502
481
120
55
120
190
47
5,762
47
4,992
1,248
3,850
1,248
2,056
514
634
514
514
5145146345142,0561,2483,8501,2484,992475,76247190120551204815021,2445022,0087862,6677863,1468923,4438923,5691,0913,9421,0914,3661,7765,3481,7767,1042,3593,5112,3599,4372,66012,9382,66010,6402,5002,5002,50010,0014,4199,9904,41917,6779409409409402,2642,2642,2642,264
       Short-term Investments 
0
0
0
0
4,407
4,407
4,407
4,407
18,238
4,560
0
4,560
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,407
4,4070000000000000000000000000000000000000000000000004,56004,56018,2384,4074,4074,4074,4070000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89
22
94
22
157
39
156
39
160
40
157
40
114
28
124
28
123
31
128
31
0
0
16
0
85
21
422
21
263
66
39
66
55
14
235
14
673
168
484
168
168
1681684841686731423514556639662632142221850160031128311232812428114401574016039156391572294228900000000000000000000
       Other Current Assets 
9
9
9
9
2
2
2
2
5
1
11
1
12
3
3
3
272
68
251
68
66
17
87
17
60
15
82
15
61
15
57
15
55
14
60
14
19
5
40
5
0
0
16
0
15
4
0
4
5
1
16
1
15
4
28
4
541
135
466
135
135
135135466135541428415116154041501600540519146014551557156115821560178717666825168272333121111522229999
   > Long-term Assets 
1,205
1,205
1,205
1,205
1,330
1,330
1,330
1,330
17,677
4,419
0
4,419
10,001
2,500
2,500
2,500
15,445
3,861
17,405
3,861
20,155
5,039
19,737
5,039
21,042
5,260
22,174
5,260
18,406
4,601
18,514
4,601
18,658
4,664
18,760
4,664
18,959
4,740
43
4,740
0
0
0
0
1
0
1
0
25
6
24
6
76
19
64
19
4
1
5
1
1
1151419641976624625010100004,740434,74018,9594,66418,7604,66418,6584,60118,5144,60118,4065,26022,1745,26021,0425,03919,7375,03920,1553,86117,4053,86115,4452,5002,5002,50010,0014,41904,41917,6771,3301,3301,3301,3301,2051,2051,2051,205
       Property Plant Equipment 
1,205
1,205
1,205
1,205
1,205
1,205
1,205
1,205
0
0
0
0
0
0
0
0
307
77
16,546
77
7,499
1,875
10,437
1,875
11,742
2,936
12,874
2,936
11,692
2,923
11,800
2,923
11,944
2,986
12,046
2,986
12,245
3,061
43
3,061
0
0
0
0
1
0
1
0
25
6
24
6
76
19
64
19
4
1
5
1
1
1151419641976624625010100003,061433,06112,2452,98612,0462,98611,9442,92311,8002,92311,6922,93612,8742,93611,7421,87510,4371,8757,4997716,54677307000000001,2051,2051,2051,2051,2051,2051,2051,205
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
858
215
644
215
644
161
644
161
429
107
429
107
429
107
429
107
429
107
0
107
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
215
21500000000000000000000107010742910742910742910742910742916164416164421564421585800000000000000000000
       Intangible Assets 
0
0
0
0
125
125
125
125
0
0
0
0
0
0
0
0
15,138
3,785
0
3,785
11,798
2,950
8,656
2,950
8,656
2,164
8,656
2,164
6,285
1,571
6,285
1,571
6,285
1,571
6,285
1,571
6,285
1,571
0
1,571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
125
125000000000000000000001,57101,5716,2851,5716,2851,5716,2851,5716,2851,5716,2852,1648,6562,1648,6562,9508,6562,95011,7983,78503,78515,138000000001251251251250000
> Total Liabilities 
18
18
18
18
15
15
15
15
53
13
25
13
49
12
12
12
520
130
300
130
121
30
47
30
149
37
197
37
102
26
146
26
126
32
171
32
207
52
236
52
91
23
167
23
327
82
661
82
596
149
343
149
1,284
321
495
321
1,030
258
1,899
258
258
2582581,8992581,0303214953211,2841493431495968266182327231672391522365220732171321262614626102371973714930473012113030013052012121249132513531515151518181818
   > Total Current Liabilities 
18
18
18
18
15
15
15
15
53
13
25
13
49
12
12
12
520
130
300
130
121
30
47
30
149
37
197
37
102
26
146
26
126
32
172
32
207
52
236
52
91
23
167
23
327
82
661
82
575
144
324
144
1,237
309
460
309
1,030
258
1,899
258
258
2582581,8992581,0303094603091,2371443241445758266182327231672391522365220732172321262614626102371973714930473012113030013052012121249132513531515151518181818
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
0
4
0
25
0
26
0
0
0
0
0
0
000000260250404000000000000000000000000000000000000000000000000
       Accounts payable 
18
18
18
18
15
15
15
15
53
13
0
13
26
7
7
7
308
77
53
77
48
12
32
12
74
18
177
18
81
20
143
20
86
22
148
22
147
37
218
37
0
0
90
0
293
73
634
73
480
120
258
120
153
38
161
38
565
141
1,364
141
141
1411411,36414156538161381531202581204807363473293090003721837147221482286201432081181771874123212487753773087772613013531515151518181818
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
25
0
23
6
6
6
212
53
247
53
72
18
15
18
75
19
20
19
21
5
3
5
40
10
24
10
60
15
18
15
91
23
78
23
34
9
27
9
90
24
62
24
1,059
271
274
271
465
116
535
116
116
1161165351164652712742711,059246224909279342378239115181560102410405352119201975181518725324753212666230250000000000
   > Long-term Liabilities 
18
18
18
18
15
15
15
15
53
13
0
13
26
7
7
7
308
77
53
77
48
12
32
12
74
18
177
18
81
20
143
20
86
22
-1
22
147
37
218
37
0
0
90
0
293
73
634
73
21
5
19
5
47
12
35
12
565
141
1,364
141
5
51411,36414156512351247519521736347329309000372183714722-12286201432081181771874123212487753773087772613013531515151518181818
> Total Stockholder Equity
3,459
3,459
3,459
3,459
6,663
6,663
6,663
6,663
35,867
8,967
9,976
8,967
9,964
2,491
2,491
2,491
25,822
6,459
30,294
6,459
29,628
7,407
23,381
7,407
28,214
7,053
27,562
7,053
22,890
5,723
22,523
5,723
22,269
5,567
22,217
5,567
22,039
5,510
2,641
5,510
1,917
479
1,092
479
255
64
-159
64
-113
-28
5,498
-28
3,854
964
3,682
964
2,244
561
-310
561
561
561561-3105612,2449643,6829643,854-285,498-28-11364-159642554791,0924791,9175,5102,6415,51022,0395,56722,2175,56722,2695,72322,5235,72322,8907,05327,5627,05328,2147,40723,3817,40729,6286,45930,2946,45925,8222,4912,4912,4919,9648,9679,9768,96735,8676,6636,6636,6636,6633,4593,4593,4593,459
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59,819
0
65,954
16,488
0
16,488
0
0
66,192
0
66,192
16,548
0
16,548
66,192
16,548
66,192
16,548
66,368
16,592
66,368
16,592
68,403
17,101
68,803
17,101
67,519
16,880
67,137
16,880
0
0
76,371
0
94,380
23,595
78,667
23,595
23,595
23,59523,59578,66723,59594,380076,3710016,88067,13716,88067,51917,10168,80317,10168,40316,59266,36816,59266,36816,54866,19216,54866,19216,548016,54866,192066,1920016,488016,48865,954059,8190000000000000000000000
   Retained Earnings 
-375
-375
-375
-375
2,127
2,127
2,127
2,127
19,219
4,805
-5,829
4,805
-5,938
-1,485
-1,485
-1,485
-18,518
-4,630
-30,186
-4,630
-31,696
-7,924
-38,055
-7,924
-39,654
-9,914
-39,612
-9,914
-44,516
-11,129
-44,868
-11,129
-45,030
-11,257
-45,129
-11,257
-44,354
-11,089
-63,541
-11,089
-64,451
-16,113
-65,644
-16,113
-68,211
-17,053
-69,096
-17,053
-69,424
-17,356
-70,395
-17,356
-72,584
-18,146
-74,453
-18,146
-85,587
-21,397
-81,404
-21,397
-21,397
-21,397-21,397-81,404-21,397-85,587-18,146-74,453-18,146-72,584-17,356-70,395-17,356-69,424-17,053-69,096-17,053-68,211-16,113-65,644-16,113-64,451-11,089-63,541-11,089-44,354-11,257-45,129-11,257-45,030-11,129-44,868-11,129-44,516-9,914-39,612-9,914-39,654-7,924-38,055-7,924-31,696-4,630-30,186-4,630-18,518-1,485-1,485-1,485-5,9384,805-5,8294,80519,2192,1272,1272,1272,127-375-375-375-375
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
3,834
3,834
3,834
3,834
4,536
4,536
4,536
4,536
16,648
4,162
15,805
4,162
15,902
3,976
3,976
3,976
44,340
11,100
60,481
11,100
61,067
15,374
1,440
15,374
1,820
548
67,139
548
67,479
16,962
1,269
16,962
1,299
830
67,508
830
69
112
-10
112
0
0
369
0
63
16
134
16
1,790
449
8,753
449
76,433
19,110
1,769
19,110
1,833
-1,636
2,479
-1,636
0
0-1,6362,479-1,6361,83319,1101,76919,11076,4334498,7534491,790161341663036900112-101126983067,5088301,29916,9621,26916,96267,47954867,1395481,82015,3741,44015,37461,06711,10060,48111,10044,3403,9763,9763,97615,9024,16215,8054,16216,6484,5364,5364,5364,5363,8343,8343,8343,834



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-4,733
Operating Income-4,733-4,733
 
Operating Expense (+$)
Research Development991
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense4,733991
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-4,733
Net Interest Income0
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-4,733-4,733
EBIT - interestExpense = -4,733
-4,733
-4,134
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-4,733-4,733
Earnings Before Interest and Taxes (EBITDA)-4,731
 
After tax Income (+$)
Income Before Tax-4,733
Tax Provision--787
Net Income From Continuing Ops-5,431-3,947
Net Income-4,134
Net Income Applicable To Common Shares-3,976
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses4,733
Total Other Income/Expenses Net-0
 

Technicals of OKYO Pharma Ltd ADR

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

OKYO Pharma Ltd ADR Daily Moving Averages ChartOKYO Pharma Ltd ADR Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of OKYO Pharma Ltd ADR:

  • The Moving Average Convergence/Divergence (MACD) is -0.005. The Moving Average Convergence/Divergence (MACD) below zero is a bearish sign. -1
  • The MACD is lower than the signal line. This is a bearish indication. -1
OKYO Pharma Ltd ADR Daily Moving Average Convergence/Divergence (MACD) ChartOKYO Pharma Ltd ADR Daily Moving Average Convergence/Divergence (MACD) Chart
1.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

The ADX helps you determine the strength of a trend. Let's take a look of the ADX of OKYO Pharma Ltd ADR:

  • The ADX is 31.268. Strong Trend. +1
  • The ADX is rising, the current trend is strengthening. +1
  • The +DI is higher than the -DI. The current trend is up. +2
OKYO Pharma Ltd ADR Daily Directional Movement Index (DMI) ChartOKYO Pharma Ltd ADR Daily Directional Movement Index (DMI) Chart
1.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..
  • The Parabolic SAR is higher than the price. The current trend is down. -2
  • OKYO Pharma Ltd ADR Daily Parabolic SAR ChartOKYO Pharma Ltd ADR Daily Parabolic SAR Chart

    2. Momentum Indicators

    2.1 Relative Strength Index (RSI)

    Measures the speed and change of price movements.

    • Leading momentum indicator, meaning the signals are instant.
    • Ranges between 0 and 100.
    • Above 70 is considered overbought.
    • Below 30 is considered oversold.
    • Above or below 50 can also be used to determine price trend or support and resistance.
    • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
    • Can be used in many different ways
    • The RSI is above 50. +1